The National Institute for Clinical Excellence's next work programme will consider of treatments for cancer and heart disease. Thrombolytic drugs for heart attacks, caelyx for ovarian cancer and STI-571 for chronic myeloid leukaemia will be appraised. Other treatments NICE will consider in the next wave will include surgical procedures for ...